Tolebrutinib meets primary endpoint in HERCULES phase 3 study
Phase 3 study results will form the basis for future discussions with global regulatory authorities
Phase 3 study results will form the basis for future discussions with global regulatory authorities
Brian Foard will lead the Specialty Care GBU ad interim, effective immediately.
Subscribe To Our Newsletter & Stay Updated